UCB (UCBJY) News Today → How Biden has already won 2024 (From Porter & Company) (Ad) Free UCBJY Stock Alerts $69.68 +1.26 (+1.84%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartDividendFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartDividendFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 31 at 6:26 AM | americanbankingnews.comUCB SA (OTCMKTS:UCBJY) Short Interest Up 38.6% in MayApril 25, 2024 | finance.yahoo.comUCB SA's Dividend AnalysisDecember 29, 2023 | seekingalpha.comDrugmakers reportedly planning to raise prices on 500+ drugs in January (update)December 29, 2023 | msn.comDrugmakers reportedly planning to raise prices on 500+ drugs in JanuaryDecember 28, 2023 | msn.comFDA’s new drug approvals for 2023 rise 51% from last yearDecember 1, 2023 | finance.yahoo.comUCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual MeetingNovember 14, 2023 | finance.yahoo.comUCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque PsoriasisOctober 18, 2023 | msn.comFDA approves UCB's Bimzelx for plaque psoriasisOctober 4, 2023 | benzinga.comUCB presents late-breaking posters at Child Neurology Society MeetingSeptember 15, 2023 | msn.comEMA advisors recommend many new meds at latest meetingAugust 31, 2023 | markets.businessinsider.comSkin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst AssertsAugust 26, 2023 | msn.comCrohn's disease drugmakers set to benefit from expected rise in casesApril 13, 2023 | msn.comUCB (UCBJY) Declares $0.73 DividendApril 6, 2023 | wsj.comUnited Commercial Bank Ltd.March 20, 2023 | benzinga.comBimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 WeeksDecember 23, 2022 | finance.yahoo.comUCB SA (UCBJY) Stock Historical Prices & Data - Yahoo FinanceDecember 9, 2022 | seekingalpha.comUCB drug meets main goals of 2 phase 3 trials for painful skin disorderNovember 8, 2022 | benzinga.comUCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022September 24, 2022 | benzinga.comUCB presents latest data from generalized myasthenia gravis portfolio at AANEM meetingSeptember 22, 2022 | finance.yahoo.comUCB SA (UCB.BR)September 17, 2022 | reuters.comUCB.BR - UCB SA | Stock Price & Latest News | ReutersSeptember 2, 2022 | benzinga.comUCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV CongressMay 11, 2022 | finance.yahoo.comUCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravisMay 4, 2022 | markets.businessinsider.comJAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)March 29, 2022 | markets.businessinsider.comFINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)March 28, 2022 | finance.yahoo.comUCB's Rare Childhood Epilepsy Drug Scores FDA ApprovalMarch 28, 2022 | seekingalpha.comUCB's Fintepla gets FDA approval to treat rare childhood epilepsyMarch 7, 2022 | seekingalpha.comUCB completes $1.9B acquisition of ZogenixJanuary 21, 2022 | ca.finance.yahoo.comZogenix Surges After UCB's $1.9B Acquisition OfferJanuary 21, 2022 | seekingalpha.comUCB says second late-stage psoriatic arthritis trial for bimekizumab met main goalJanuary 20, 2022 | markets.businessinsider.comPositive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis StudyJanuary 20, 2022 | apnews.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Zogenix, Inc. MergerDecember 18, 2021 | markets.businessinsider.comPositive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis TrialDecember 18, 2021 | nasdaq.comUCBJY Real-Time QuotesOctober 16, 2021 | finance.yahoo.comUpdate on U.S. FDA Review of Biologics License Application (BLA) for bimekizumabAugust 30, 2021 | finance.yahoo.comUCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older Get UCB News Delivered to You Automatically Sign up to receive the latest news and ratings for UCBJY and its competitors with MarketBeat's FREE daily newsletter. Email Address This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. UCBJY Media Mentions By Week UCBJY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UCBJY News Sentiment▼-0.010.77▲Average Medical News Sentiment UCBJY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UCBJY Articles This Week▼20▲UCBJY Articles Average Week Get UCB News Delivered to You Automatically Sign up to receive the latest news and ratings for UCBJY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AGNPF News Today AKBLF News Today DRTSW News Today ARNI News Today ARTLW News Today ASCLF News Today AWKNF News Today AXIM News Today BSSP News Today BRRGF News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:UCBJY) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking $16T Elon Musk Crypto LeakCrypto 101 MediaWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsWrite this ticker symbol down…StocksToTradeBiden replacement revealed?Paradigm PressThis unknown company solves the biggest issue with AIManward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UCB SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
